Kindred Biosciences Inc represents a strong commitment to improving the lives of animals through innovative veterinary biologics and therapeutics. The company values include integrity, innovation, collaboration, and a dedication to scientific excellence. Kindred Biosciences is driven by a corporate philosophy that emphasizes the importance of research and development, aiming to address unmet veterinary needs and provide effective treatments for various animal species. By leveraging cutting-edge technologies and partnerships, Kindred Biosciences strives to make a positive impact on animal health, while also creating value for its shareholders.

Kindred Biosciences Inc primarily operates in the United States.

Since its establishment, Kindred Biosciences Inc has accomplished several significant milestones. The company successfully received approval from the Food and Drug Administration (FDA) for their groundbreaking therapies, such as Zimeta, Mirataz, and KIND-016. Additionally, Kindred Biosciences Inc has entered into strategic partnerships and collaborations with renowned pharmaceutical companies, enabling them to expand their research and development capabilities. These partnerships have played a pivotal role in advancing the company's pipeline, leading to the development of innovative treatments for various animal diseases. Kindred Biosciences Inc continues to exhibit strong commitment towards improving animal health and welfare through their pioneering achievements and ongoing efforts.

Kindred Biosciences Inc, a biopharmaceutical company, has a fascinating history and background. It was founded in 2012 and is headquartered in California, United States. The company specializes in developing innovative medicines for veterinary use. Kindred Biosciences is committed to enhancing the lives of pets by focusing on unmet medical needs. With a highly experienced team and state-of-the-art facilities, they strive to develop effective therapies and treatments for various animal diseases. Kindred Biosciences has gained recognition for its dedication to animal health and its successful development of novel biologics. Continuously expanding its product portfolio, the company seeks to revolutionize veterinary medicine.

The main competitors of Kindred Biosciences Inc in the market are Zoetis Inc., Elanco Animal Health Inc., and IDEXX Laboratories Inc.

Kindred Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Kindred Biosciences Inc, a biopharmaceutical company, focuses on veterinary medicine. They develop innovative therapeutics for animals, aiming to improve the lives of pets and horses. Kindred Biosciences creates drugs for various conditions that affect animals, including allergies, infections, and gastrointestinal disorders. Their mission is to provide effective and safe medications to improve the well-being of companion animals. With a strong commitment to research and development, Kindred Biosciences pioneers advancements in animal healthcare, seeking to address unmet medical needs in the veterinary industry and contribute to the overall betterment of animal health.

P/E odnos Kindred Biosciences iznosi 0.

KUV kompanije Kindred Biosciences iznosi 16,67.

AlleAktien kvalitativni skor za Kindred Biosciences je 1/10.

očekivana Kindred Biosciences promet je 21,80 mil. USD.

Profit trenutno ne može biti izračunat za Kindred Biosciences.

Kindred Biosciences Inc. is a biopharmaceutical company focused on the development of innovative animal health products. The company aims to improve animal lives and provide pet owners with innovative and effective therapies. It is divided into three main business areas: Biologics, small molecules, and diagnostics. In the field of Biologics, Kindred Biosciences develops innovative biopharmaceutical products for animals. The focus is on researching and developing antibodies and proteins that block or neutralize disease-causing target molecules. Examples include Zimeta, an injectable medication for treating fever in horses, and KIND-010, an antibody for treating atopic dermatitis in dogs. The small molecules division focuses on developing chemical compounds for treating diseases in animals. Kindred Biosciences uses its own technology platform to identify and optimize molecules that bind to specific target molecules in the body. An example is Mirataz, a topical gel for treating cats with compulsive disorders. The diagnostics division offers a wide range of tests and instruments for the rapid and reliable diagnosis of animal diseases. For example, the SUCCEED Equine Fecal Blood Test measures the worm burden in horses, allowing for targeted deworming. Kindred Biosciences also conducts extensive research and development to continuously expand and improve its portfolio of animal health products. The company collaborates closely with the veterinary community and utilizes advanced technologies and methods such as protein engineering and CRISPR/Cas9 to explore new therapeutic approaches. Overall, Kindred Biosciences offers a broad range of animal health products valued by both veterinarians and pet owners. The company stands out for its strong research and development efforts, close collaboration with the veterinary community, and innovative technologies. With a strong market position and solid growth strategy, Kindred Biosciences is an important player in the animal health products market.

Kindred Biosciences isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Kindred Biosciences trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Kindred Biosciences je US4945771099.

WKN od Kindred Biosciences je A1XA6K.

Oznaka za praćenje akcija kompanije Kindred Biosciences je KIN.

U poslednjih 12 meseci, Kindred Biosciences je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Kindred Biosciences će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Kindred Biosciences trenutno iznosi .

Kindred Biosciences isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Kindred Biosciences je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Kindred Biosciences se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Kindred Biosciences od 6. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 6. 11. 2024..

Isplata poslednje dividende izvršena je 6. 11. 2024..

U godini 2023 kompanija Kindred Biosciences je isplatila 0 USD kao dividende.

Dividende od Kindred Biosciences se isplaćuju u USD.